Latest Pharma Insights
Collegium Doubles Its ADHD Portfolio By Snagging Corium Drug
For $650m up front, Collegium will pair Azstarys, which provides both immediate and extended onset of action, with Jornay PM, its ADHD drug indicated for bedtime dosing.
Scrip - March 19, 2026
For $650m up front, Collegium will pair Azstarys, which provides both immediate and extended onset of action, with Jornay PM, its ADHD drug indicated for bedtime dosing.
Scrip - March 19, 2026
Four Validation Pillars Frame US FDA’s New Approach Methodologies For Rx And OTC Drugs
Context of use, human biological relevance, technical characterization and fitness for purpose are the key elements in validating novel methods to replace animal testing, the FDA said in a new draft guidance.
HBW Insight - March 19, 2026
Context of use, human biological relevance, technical characterization and fitness for purpose are the key elements in validating novel methods to replace animal testing, the FDA said in a new draft guidance.
HBW Insight - March 19, 2026
Numares Targets Kidney Transplantation “Blind Spot” With Metabolomics-Based Urine Test
Numares Health bets on a metabolomics-based urine test to help doctors detect kidney transplantation rejection earlier than current biomarkers, which would allow doctors to intervene earlier in trying to save the transplanted organ.
Medtech Insight - March 19, 2026
Numares Health bets on a metabolomics-based urine test to help doctors detect kidney transplantation rejection earlier than current biomarkers, which would allow doctors to intervene earlier in trying to save the transplanted organ.
Medtech Insight - March 19, 2026
ACC/AHA Guidelines Recommend Lp(a) Testing, A Boost For Drug Developers
Newly published guidelines for treating dyslipidemia recommend testing for Lipoprotein(a), a cardiovascular disease risk factor with no treatments, but with multiple candidates in the clinic.
Scrip - March 19, 2026
Newly published guidelines for treating dyslipidemia recommend testing for Lipoprotein(a), a cardiovascular disease risk factor with no treatments, but with multiple candidates in the clinic.
Scrip - March 19, 2026
Novo Nordisk Extends Wegovy Franchise With Higher-Dose Approval
The approval of Wegovy HD brings a more effective version to the lower-dose version and the oral formulation, but the company has struggled to compete with obesity rival Eli Lilly.
Scrip - March 19, 2026
The approval of Wegovy HD brings a more effective version to the lower-dose version and the oral formulation, but the company has struggled to compete with obesity rival Eli Lilly.
Scrip - March 19, 2026
Execs On The Move: March 9–13, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - March 19, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - March 19, 2026
Small Biz Bill A Big Win For Medtech Innovation: Bipartisan Legislation Awaits President’s Signature
The US Congress overwhelmingly passed legislation reauthorizing federal programs essential to smaller medtech firms in need of funding. AdvaMed says the bill is critical for medtech innovation.
Medtech Insight - March 19, 2026
The US Congress overwhelmingly passed legislation reauthorizing federal programs essential to smaller medtech firms in need of funding. AdvaMed says the bill is critical for medtech innovation.
Medtech Insight - March 19, 2026
Lilly’s Triple Agonist Retatrutide Holds Its Own In Type 2 Diabetes
The company announced the first Phase III data testing the GIP/GLP-1/glucagon agonist in diabetic patients, showing reductions in blood sugar and superior weight loss to Mounjaro.
Scrip - March 19, 2026
The company announced the first Phase III data testing the GIP/GLP-1/glucagon agonist in diabetic patients, showing reductions in blood sugar and superior weight loss to Mounjaro.
Scrip - March 19, 2026
From Boston Scientific To Danaher: Medtech’s Top Players Bet Big On M&A For Next Growth Wave
Danaher paid $9.9bn for Masimo. Abbott committed to Exact Sciences. Boston Scientific reached for Penumbra. Medtronic accelerated on multiple fronts. The window medtech spent two years waiting for is open – and the industry is moving through it fast.
Medtech Insight - March 19, 2026
Danaher paid $9.9bn for Masimo. Abbott committed to Exact Sciences. Boston Scientific reached for Penumbra. Medtronic accelerated on multiple fronts. The window medtech spent two years waiting for is open – and the industry is moving through it fast.
Medtech Insight - March 19, 2026
K-Beauty Influence: Bioré Sees South Korea As ‘Springboard,’ Ulta Builds Korean Brand Portfolio
Kao Corp. will launch Bioré in South Korea, while promoting the brand’s UV products with a global campaign featuring K-Pop band Stray Kids. Separately, Ulta Marketplace adds 17 K-Beauty Brands to the K-Beauty World platform.
HBW Insight - March 19, 2026
Kao Corp. will launch Bioré in South Korea, while promoting the brand’s UV products with a global campaign featuring K-Pop band Stray Kids. Separately, Ulta Marketplace adds 17 K-Beauty Brands to the K-Beauty World platform.
HBW Insight - March 19, 2026
Aclaris Advances Atopic Dermatitis Ambitions
Phase II results evaluating the anti-TSLP drug bosakitug are expected in the fourth quarter. Aclaris is pitching the asset as having best-in-class potential in a currently open field.
Scrip - March 19, 2026
Phase II results evaluating the anti-TSLP drug bosakitug are expected in the fourth quarter. Aclaris is pitching the asset as having best-in-class potential in a currently open field.
Scrip - March 19, 2026
In Lupin-Zydus Semaglutide Deal, Product Differentiation Is Key
Zydus’s investment in a differentiated drug-device combination for semaglutide has led to a win-win GLP-1 co-marketing deal with Lupin, even as the Indian drug regulator keeps a watch on advertising activities.
Generics Bulletin - March 19, 2026
Zydus’s investment in a differentiated drug-device combination for semaglutide has led to a win-win GLP-1 co-marketing deal with Lupin, even as the Indian drug regulator keeps a watch on advertising activities.
Generics Bulletin - March 19, 2026
Best-In-Class Claims Grow For Kelun/Merck’s Sac-TMT In Lung Cancer
The China-only result bodes well for Merck’s global studies, with Jefferies analysts convinced Sac-TMT will confirm superiority to TROP2 ADC competitors and more.
Scrip - March 19, 2026
The China-only result bodes well for Merck’s global studies, with Jefferies analysts convinced Sac-TMT will confirm superiority to TROP2 ADC competitors and more.
Scrip - March 19, 2026
Sandoz Divests Generics Portfolio In Sub-Saharan Africa To Strides
After creating a new biosimilars unit, Sandoz is now divesting its generics portfolio in Sub-Saharan Africa to the Strides Pharma group. Strides will acquire or license these brands for an initial $12m plus royalty, placing it among the top five firms in the region.
Generics Bulletin - March 19, 2026
After creating a new biosimilars unit, Sandoz is now divesting its generics portfolio in Sub-Saharan Africa to the Strides Pharma group. Strides will acquire or license these brands for an initial $12m plus royalty, placing it among the top five firms in the region.
Generics Bulletin - March 19, 2026
Executives On The Move: Five CEOs And CFOs Among This Week’s Changes
Recent moves in the industry include C-suite changes at BiomX and Novelty Nobility, plus Novartis gets a new board member.
Scrip - March 19, 2026
Recent moves in the industry include C-suite changes at BiomX and Novelty Nobility, plus Novartis gets a new board member.
Scrip - March 19, 2026
‘This Is A Global Problem’ – Chair Keon Sets Out IGBA’s Priorities For 2026
Speaking to Generics Bulletin on the sidelines of the AAM’s Access! 2026 conference, IGBA chair for 2026 Jim Keon – also president of the CGPA and Biosimilars Canada – discussed IP abuses, supply challenges, biosimilar streamlining and the importance of giving the off-patent industry a global voice.
Generics Bulletin - March 19, 2026
Speaking to Generics Bulletin on the sidelines of the AAM’s Access! 2026 conference, IGBA chair for 2026 Jim Keon – also president of the CGPA and Biosimilars Canada – discussed IP abuses, supply challenges, biosimilar streamlining and the importance of giving the off-patent industry a global voice.
Generics Bulletin - March 19, 2026
Spanish Consumers Embrace Self-Care But Barriers Remain
A new ANEFP survey shows that while most Spanish consumers see self-care as essential to good health, gaps in knowledge, mental health support and broader socio?economic pressures continue to limit how effectively it is practised.
HBW Insight - March 19, 2026
A new ANEFP survey shows that while most Spanish consumers see self-care as essential to good health, gaps in knowledge, mental health support and broader socio?economic pressures continue to limit how effectively it is practised.
HBW Insight - March 19, 2026
How a CDMO Created a Custom Vaccine Development Project
Inside the operational, technical, and strategic decisions behind scaling a complex sterile vaccine program in under two years
Scrip - March 19, 2026
Inside the operational, technical, and strategic decisions behind scaling a complex sterile vaccine program in under two years
Scrip - March 19, 2026
Cognito Shows Off More Positive Data For Device-Based Alzheimer’s Treatment
Cognito Therapeutics has revealed data from its OVERTURE feasibility study backing up the ability of its non-invasive Spectris headset to treat Alzheimer’s via the stimulation of gamma oscillations. The company is hoping to launch the device in 2027
Medtech Insight - March 19, 2026
Cognito Therapeutics has revealed data from its OVERTURE feasibility study backing up the ability of its non-invasive Spectris headset to treat Alzheimer’s via the stimulation of gamma oscillations. The company is hoping to launch the device in 2027
Medtech Insight - March 19, 2026
Samsung Bioepis Partners With G2GBIO For Long-Acting Semaglutide
Samsung Bioepis’ explorations for an alternate semaglutide formulation will be powered by G2GBIO’s microsphere technology.
Generics Bulletin - March 19, 2026
Samsung Bioepis’ explorations for an alternate semaglutide formulation will be powered by G2GBIO’s microsphere technology.
Generics Bulletin - March 19, 2026
Biosimilars Boost Stada Ahead Of CapVest Takeover
As Stada awaits the imminent closure of a deal that will see it come under the ownership of CapVest, the firm has reported 2025 sales that grew by 6% to €4.3bn, boosted by a double-digit biosimilars increase that drove Specialty sales above €1bn for the first time.
Generics Bulletin - March 19, 2026
As Stada awaits the imminent closure of a deal that will see it come under the ownership of CapVest, the firm has reported 2025 sales that grew by 6% to €4.3bn, boosted by a double-digit biosimilars increase that drove Specialty sales above €1bn for the first time.
Generics Bulletin - March 19, 2026
Flovent Withdrawal Exposes Medicaid Loophole In Generic Drug Pricing
A Senate report finds GSK’s withdrawal of Flovent and shift to an authorized generic increased costs, restricted access and disrupted asthma care, while helping the company avoid Medicaid rebates, raising broader concerns over pricing loopholes.
Generics Bulletin - March 19, 2026
A Senate report finds GSK’s withdrawal of Flovent and shift to an authorized generic increased costs, restricted access and disrupted asthma care, while helping the company avoid Medicaid rebates, raising broader concerns over pricing loopholes.
Generics Bulletin - March 19, 2026
Kintor’s Male Hair Loss Drug Returns With Phase III Win
Kintor's topical androgen receptor inhibitor KX-826 posts win in China Phase III trial in male androgenetic alopecia, following a Phase III setback in 2023.
Scrip - March 19, 2026
Kintor's topical androgen receptor inhibitor KX-826 posts win in China Phase III trial in male androgenetic alopecia, following a Phase III setback in 2023.
Scrip - March 19, 2026
California EPR Stakeholder Reports Due May 31 Will Shape Fees Under Program
Circular Action Alliance, the Producer Responsibility Organization in charge of implementing California’s EPR program, urges single-use packaging producers to comply with an upcoming May 31 deadline, which will shape proposed fees.
HBW Insight - March 19, 2026
Circular Action Alliance, the Producer Responsibility Organization in charge of implementing California’s EPR program, urges single-use packaging producers to comply with an upcoming May 31 deadline, which will shape proposed fees.
HBW Insight - March 19, 2026
Collegium Doubles Its ADHD Portfolio By Snagging Corium Drug
For $650m up front, Collegium will pair Azstarys, which provides both immediate and extended onset of action, with Jornay PM, its ADHD drug indicated for bedtime dosing.
Scrip - March 19, 2026
For $650m up front, Collegium will pair Azstarys, which provides both immediate and extended onset of action, with Jornay PM, its ADHD drug indicated for bedtime dosing.
Scrip - March 19, 2026
ACC/AHA Guidelines Recommend Lp(a) Testing, A Boost For Drug Developers
Newly published guidelines for treating dyslipidemia recommend testing for Lipoprotein(a), a cardiovascular disease risk factor with no treatments, but with multiple candidates in the clinic.
Scrip - March 19, 2026
Newly published guidelines for treating dyslipidemia recommend testing for Lipoprotein(a), a cardiovascular disease risk factor with no treatments, but with multiple candidates in the clinic.
Scrip - March 19, 2026
Novo Nordisk Extends Wegovy Franchise With Higher-Dose Approval
The approval of Wegovy HD brings a more effective version to the lower-dose version and the oral formulation, but the company has struggled to compete with obesity rival Eli Lilly.
Scrip - March 19, 2026
The approval of Wegovy HD brings a more effective version to the lower-dose version and the oral formulation, but the company has struggled to compete with obesity rival Eli Lilly.
Scrip - March 19, 2026
Lilly’s Triple Agonist Retatrutide Holds Its Own In Type 2 Diabetes
The company announced the first Phase III data testing the GIP/GLP-1/glucagon agonist in diabetic patients, showing reductions in blood sugar and superior weight loss to Mounjaro.
Scrip - March 19, 2026
The company announced the first Phase III data testing the GIP/GLP-1/glucagon agonist in diabetic patients, showing reductions in blood sugar and superior weight loss to Mounjaro.
Scrip - March 19, 2026
Aclaris Advances Atopic Dermatitis Ambitions
Phase II results evaluating the anti-TSLP drug bosakitug are expected in the fourth quarter. Aclaris is pitching the asset as having best-in-class potential in a currently open field.
Scrip - March 19, 2026
Phase II results evaluating the anti-TSLP drug bosakitug are expected in the fourth quarter. Aclaris is pitching the asset as having best-in-class potential in a currently open field.
Scrip - March 19, 2026
Best-In-Class Claims Grow For Kelun/Merck’s Sac-TMT In Lung Cancer
The China-only result bodes well for Merck’s global studies, with Jefferies analysts convinced Sac-TMT will confirm superiority to TROP2 ADC competitors and more.
Scrip - March 19, 2026
The China-only result bodes well for Merck’s global studies, with Jefferies analysts convinced Sac-TMT will confirm superiority to TROP2 ADC competitors and more.
Scrip - March 19, 2026
Executives On The Move: Five CEOs And CFOs Among This Week’s Changes
Recent moves in the industry include C-suite changes at BiomX and Novelty Nobility, plus Novartis gets a new board member.
Scrip - March 19, 2026
Recent moves in the industry include C-suite changes at BiomX and Novelty Nobility, plus Novartis gets a new board member.
Scrip - March 19, 2026
How a CDMO Created a Custom Vaccine Development Project
Inside the operational, technical, and strategic decisions behind scaling a complex sterile vaccine program in under two years
Scrip - March 19, 2026
Inside the operational, technical, and strategic decisions behind scaling a complex sterile vaccine program in under two years
Scrip - March 19, 2026
Kintor’s Male Hair Loss Drug Returns With Phase III Win
Kintor's topical androgen receptor inhibitor KX-826 posts win in China Phase III trial in male androgenetic alopecia, following a Phase III setback in 2023.
Scrip - March 19, 2026
Kintor's topical androgen receptor inhibitor KX-826 posts win in China Phase III trial in male androgenetic alopecia, following a Phase III setback in 2023.
Scrip - March 19, 2026
Numares Targets Kidney Transplantation “Blind Spot” With Metabolomics-Based Urine Test
Numares Health bets on a metabolomics-based urine test to help doctors detect kidney transplantation rejection earlier than current biomarkers, which would allow doctors to intervene earlier in trying to save the transplanted organ.
Medtech Insight - March 19, 2026
Numares Health bets on a metabolomics-based urine test to help doctors detect kidney transplantation rejection earlier than current biomarkers, which would allow doctors to intervene earlier in trying to save the transplanted organ.
Medtech Insight - March 19, 2026
Execs On The Move: March 9–13, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - March 19, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - March 19, 2026
Small Biz Bill A Big Win For Medtech Innovation: Bipartisan Legislation Awaits President’s Signature
The US Congress overwhelmingly passed legislation reauthorizing federal programs essential to smaller medtech firms in need of funding. AdvaMed says the bill is critical for medtech innovation.
Medtech Insight - March 19, 2026
The US Congress overwhelmingly passed legislation reauthorizing federal programs essential to smaller medtech firms in need of funding. AdvaMed says the bill is critical for medtech innovation.
Medtech Insight - March 19, 2026
From Boston Scientific To Danaher: Medtech’s Top Players Bet Big On M&A For Next Growth Wave
Danaher paid $9.9bn for Masimo. Abbott committed to Exact Sciences. Boston Scientific reached for Penumbra. Medtronic accelerated on multiple fronts. The window medtech spent two years waiting for is open – and the industry is moving through it fast.
Medtech Insight - March 19, 2026
Danaher paid $9.9bn for Masimo. Abbott committed to Exact Sciences. Boston Scientific reached for Penumbra. Medtronic accelerated on multiple fronts. The window medtech spent two years waiting for is open – and the industry is moving through it fast.
Medtech Insight - March 19, 2026
Cognito Shows Off More Positive Data For Device-Based Alzheimer’s Treatment
Cognito Therapeutics has revealed data from its OVERTURE feasibility study backing up the ability of its non-invasive Spectris headset to treat Alzheimer’s via the stimulation of gamma oscillations. The company is hoping to launch the device in 2027
Medtech Insight - March 19, 2026
Cognito Therapeutics has revealed data from its OVERTURE feasibility study backing up the ability of its non-invasive Spectris headset to treat Alzheimer’s via the stimulation of gamma oscillations. The company is hoping to launch the device in 2027
Medtech Insight - March 19, 2026
Four Validation Pillars Frame US FDA’s New Approach Methodologies For Rx And OTC Drugs
Context of use, human biological relevance, technical characterization and fitness for purpose are the key elements in validating novel methods to replace animal testing, the FDA said in a new draft guidance.
HBW Insight - March 19, 2026
Context of use, human biological relevance, technical characterization and fitness for purpose are the key elements in validating novel methods to replace animal testing, the FDA said in a new draft guidance.
HBW Insight - March 19, 2026
Spanish Consumers Embrace Self-Care But Barriers Remain
A new ANEFP survey shows that while most Spanish consumers see self-care as essential to good health, gaps in knowledge, mental health support and broader socio?economic pressures continue to limit how effectively it is practised.
HBW Insight - March 19, 2026
A new ANEFP survey shows that while most Spanish consumers see self-care as essential to good health, gaps in knowledge, mental health support and broader socio?economic pressures continue to limit how effectively it is practised.
HBW Insight - March 19, 2026
California EPR Stakeholder Reports Due May 31 Will Shape Fees Under Program
Circular Action Alliance, the Producer Responsibility Organization in charge of implementing California’s EPR program, urges single-use packaging producers to comply with an upcoming May 31 deadline, which will shape proposed fees.
HBW Insight - March 19, 2026
Circular Action Alliance, the Producer Responsibility Organization in charge of implementing California’s EPR program, urges single-use packaging producers to comply with an upcoming May 31 deadline, which will shape proposed fees.
HBW Insight - March 19, 2026
K-Beauty Influence: Bioré Sees South Korea As ‘Springboard,’ Ulta Builds Korean Brand Portfolio
Kao Corp. will launch Bioré in South Korea, while promoting the brand’s UV products with a global campaign featuring K-Pop band Stray Kids. Separately, Ulta Marketplace adds 17 K-Beauty Brands to the K-Beauty World platform.
HBW Insight - March 19, 2026
Kao Corp. will launch Bioré in South Korea, while promoting the brand’s UV products with a global campaign featuring K-Pop band Stray Kids. Separately, Ulta Marketplace adds 17 K-Beauty Brands to the K-Beauty World platform.
HBW Insight - March 19, 2026
In Lupin-Zydus Semaglutide Deal, Product Differentiation Is Key
Zydus’s investment in a differentiated drug-device combination for semaglutide has led to a win-win GLP-1 co-marketing deal with Lupin, even as the Indian drug regulator keeps a watch on advertising activities.
Generics Bulletin - March 19, 2026
Zydus’s investment in a differentiated drug-device combination for semaglutide has led to a win-win GLP-1 co-marketing deal with Lupin, even as the Indian drug regulator keeps a watch on advertising activities.
Generics Bulletin - March 19, 2026
Sandoz Divests Generics Portfolio In Sub-Saharan Africa To Strides
After creating a new biosimilars unit, Sandoz is now divesting its generics portfolio in Sub-Saharan Africa to the Strides Pharma group. Strides will acquire or license these brands for an initial $12m plus royalty, placing it among the top five firms in the region.
Generics Bulletin - March 19, 2026
After creating a new biosimilars unit, Sandoz is now divesting its generics portfolio in Sub-Saharan Africa to the Strides Pharma group. Strides will acquire or license these brands for an initial $12m plus royalty, placing it among the top five firms in the region.
Generics Bulletin - March 19, 2026
‘This Is A Global Problem’ – Chair Keon Sets Out IGBA’s Priorities For 2026
Speaking to Generics Bulletin on the sidelines of the AAM’s Access! 2026 conference, IGBA chair for 2026 Jim Keon – also president of the CGPA and Biosimilars Canada – discussed IP abuses, supply challenges, biosimilar streamlining and the importance of giving the off-patent industry a global voice.
Generics Bulletin - March 19, 2026
Speaking to Generics Bulletin on the sidelines of the AAM’s Access! 2026 conference, IGBA chair for 2026 Jim Keon – also president of the CGPA and Biosimilars Canada – discussed IP abuses, supply challenges, biosimilar streamlining and the importance of giving the off-patent industry a global voice.
Generics Bulletin - March 19, 2026
Samsung Bioepis Partners With G2GBIO For Long-Acting Semaglutide
Samsung Bioepis’ explorations for an alternate semaglutide formulation will be powered by G2GBIO’s microsphere technology.
Generics Bulletin - March 19, 2026
Samsung Bioepis’ explorations for an alternate semaglutide formulation will be powered by G2GBIO’s microsphere technology.
Generics Bulletin - March 19, 2026
Biosimilars Boost Stada Ahead Of CapVest Takeover
As Stada awaits the imminent closure of a deal that will see it come under the ownership of CapVest, the firm has reported 2025 sales that grew by 6% to €4.3bn, boosted by a double-digit biosimilars increase that drove Specialty sales above €1bn for the first time.
Generics Bulletin - March 19, 2026
As Stada awaits the imminent closure of a deal that will see it come under the ownership of CapVest, the firm has reported 2025 sales that grew by 6% to €4.3bn, boosted by a double-digit biosimilars increase that drove Specialty sales above €1bn for the first time.
Generics Bulletin - March 19, 2026
Flovent Withdrawal Exposes Medicaid Loophole In Generic Drug Pricing
A Senate report finds GSK’s withdrawal of Flovent and shift to an authorized generic increased costs, restricted access and disrupted asthma care, while helping the company avoid Medicaid rebates, raising broader concerns over pricing loopholes.
Generics Bulletin - March 19, 2026
A Senate report finds GSK’s withdrawal of Flovent and shift to an authorized generic increased costs, restricted access and disrupted asthma care, while helping the company avoid Medicaid rebates, raising broader concerns over pricing loopholes.
Generics Bulletin - March 19, 2026
Execs On The Move: February 2026
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
In Vivo - March 18, 2026
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
In Vivo - March 18, 2026
Adapt To Survive: Private Hospitals In A High-Pressure Landscape
Payers' and patients' growing preference for outpatient care is increasing pressure on private providers to continually reassess how they deliver value. Jean-Philippe Grosmaitre and Guillaume Duparc, partners at L.E.K. Consulting, outlined growth opportunities available to private hospitals.
In Vivo - March 18, 2026
Payers' and patients' growing preference for outpatient care is increasing pressure on private providers to continually reassess how they deliver value. Jean-Philippe Grosmaitre and Guillaume Duparc, partners at L.E.K. Consulting, outlined growth opportunities available to private hospitals.
In Vivo - March 18, 2026
An Irregular Regulatory Agency: Industry Contends With An Unpredictable FDA
A series of surprise rejections has made for an FDA that drug and vaccine manufacturers are finding much harder to read than in years past.
In Vivo - March 18, 2026
A series of surprise rejections has made for an FDA that drug and vaccine manufacturers are finding much harder to read than in years past.
In Vivo - March 18, 2026